NZ703560A - Method for activating helper t cell - Google Patents

Method for activating helper t cell

Info

Publication number
NZ703560A
NZ703560A NZ703560A NZ70356011A NZ703560A NZ 703560 A NZ703560 A NZ 703560A NZ 703560 A NZ703560 A NZ 703560A NZ 70356011 A NZ70356011 A NZ 70356011A NZ 703560 A NZ703560 A NZ 703560A
Authority
NZ
New Zealand
Prior art keywords
hla
drb1
peptide
seq
molecule
Prior art date
Application number
NZ703560A
Other languages
English (en)
Inventor
Haruo Sugiyama
Shinji Sogo
Masayoshi Sato
Ryuki Kitamoto
Yoshihiro Goto
Original Assignee
Otsuka Pharma Co Ltd
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd, Int Inst Cancer Immunology Inc filed Critical Otsuka Pharma Co Ltd
Publication of NZ703560A publication Critical patent/NZ703560A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ703560A 2010-10-05 2011-10-04 Method for activating helper t cell NZ703560A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010225806 2010-10-05
NZ609460A NZ609460A (en) 2010-10-05 2011-10-04 Method for activating helper t cell

Publications (1)

Publication Number Publication Date
NZ703560A true NZ703560A (en) 2016-11-25

Family

ID=45927725

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ703560A NZ703560A (en) 2010-10-05 2011-10-04 Method for activating helper t cell
NZ609460A NZ609460A (en) 2010-10-05 2011-10-04 Method for activating helper t cell

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ609460A NZ609460A (en) 2010-10-05 2011-10-04 Method for activating helper t cell

Country Status (21)

Country Link
US (2) US10654892B2 (https=)
EP (1) EP2626418B8 (https=)
JP (3) JP6134139B2 (https=)
KR (3) KR20140009168A (https=)
CN (2) CN105802910A (https=)
AR (1) AR083295A1 (https=)
AU (1) AU2011313327B2 (https=)
BR (1) BR112013008230A2 (https=)
CA (1) CA2813557C (https=)
CO (1) CO6710946A2 (https=)
EA (1) EA037547B1 (https=)
ES (1) ES2849187T3 (https=)
IL (2) IL225536B (https=)
MX (2) MX361299B (https=)
MY (1) MY170306A (https=)
NZ (2) NZ703560A (https=)
PH (1) PH12013500654A1 (https=)
SG (3) SG189287A1 (https=)
TW (2) TW201623616A (https=)
WO (1) WO2012046730A1 (https=)
ZA (1) ZA201303056B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101580538B (zh) 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
ES2542141T3 (es) 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
PL2010209T3 (pl) 2006-04-10 2017-04-28 Sloan Kettering Inst For Cancer Res Immunogeniczne peptydy WT-1 i sposoby ich użycia
MX2009009168A (es) * 2007-02-27 2009-09-07 Int Inst Cancer Immunology Inc Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
SG189287A1 (en) * 2010-10-05 2013-05-31 Int Inst Cancer Immunology Inc Method for activating helper t cell
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
EP2896693A4 (en) * 2012-09-12 2016-10-12 Int Inst Cancer Immunology Inc ANTIGEN SPECIFIC HELPER T CELL RECEPTOR GENES
WO2014098012A1 (ja) * 2012-12-17 2014-06-26 大塚製薬株式会社 ヘルパーt細胞の活性化方法
EP3769782A1 (en) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
MY171854A (en) 2013-03-29 2019-11-05 Sumitomo Dainippon Pharma Co Ltd Wt1 antigen peptide conjugate vaccine
EP3112378B1 (en) * 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
CA2974066C (en) 2014-12-25 2025-05-06 International Institute Of Cancer Immunology, Inc. METHOD FOR MODIFYING A T LYMPHOCYTE POPULATION
CN106565836B (zh) * 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 高亲和力的可溶性pdl-1分子
ES2946188T3 (es) 2016-11-09 2023-07-13 Univ Osaka Procedimiento para modificar una población de linfocitos T
EP3549957A4 (en) * 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER
WO2019131722A1 (ja) * 2017-12-27 2019-07-04 大日本住友製薬株式会社 Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物
EP4036235A1 (en) * 2018-02-15 2022-08-03 National University Corporation Asahikawa Medical University Cancer antigen peptide
MX2021001938A (es) * 2018-08-22 2021-04-19 Fred Hutchinson Cancer Center Inmunoterapia dirigida a antigenos kras o her2.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
CN1560078B (zh) 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
ATE399179T1 (de) 1998-09-30 2008-07-15 Corixa Corp Zusammensetzungen und verfahren für wt1- spezifische immunotherapie
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CA2401070A1 (en) 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
ES2298353T3 (es) 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. Peptido wt1 modificado.
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
CN1320923C (zh) 2001-06-29 2007-06-13 中外制药株式会社 含有基于癌抑制基因wt1的产物的癌抗原和阳离子脂质体的癌疫苗
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
US20050002951A1 (en) 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004024175A1 (ja) 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
ATE442378T1 (de) 2002-09-20 2009-09-15 Int Inst Cancer Immunology Inc Substituierte wt1-peptide
EP1584627B1 (en) 2003-01-15 2009-10-07 International Institute of Cancer Immunology, Inc. Dimerized peptide
KR101431312B1 (ko) 2003-06-27 2014-08-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ1 백신 적응 환자의 선택 방법
CN101580538B (zh) 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
ES2556232T3 (es) 2004-03-31 2016-01-14 International Institute Of Cancer Immunology, Inc. Péptidos antigénicos del cáncer derivados de WT1
US7608769B2 (en) * 2004-05-12 2009-10-27 First Act, Inc. Packaged drum set
JP4719876B2 (ja) 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
ES2542141T3 (es) 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
US7420880B2 (en) 2005-12-29 2008-09-02 Timex Group B.V. Multimode electronic device with calibrating/setting mechanism
ES2587980T3 (es) 2006-02-22 2016-10-28 International Institute Of Cancer Immunology, Inc Péptido WT1 con restricción HLA-A*3303 y composición farmacéutica que lo contiene
PL2010209T3 (pl) 2006-04-10 2017-04-28 Sloan Kettering Inst For Cancer Res Immunogeniczne peptydy WT-1 i sposoby ich użycia
CA2670658A1 (en) 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
MX2009009168A (es) 2007-02-27 2009-09-07 Int Inst Cancer Immunology Inc Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
EP3173480A3 (en) 2007-03-05 2017-08-16 International Institute of Cancer Immunology, Inc. Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
SG189287A1 (en) * 2010-10-05 2013-05-31 Int Inst Cancer Immunology Inc Method for activating helper t cell
WO2014098012A1 (ja) 2012-12-17 2014-06-26 大塚製薬株式会社 ヘルパーt細胞の活性化方法

Also Published As

Publication number Publication date
EP2626418A1 (en) 2013-08-14
BR112013008230A2 (pt) 2016-06-14
NZ609460A (en) 2015-07-31
MX2013003884A (es) 2013-07-05
EP2626418B1 (en) 2020-12-09
KR102171794B1 (ko) 2020-10-29
MY170306A (en) 2019-07-17
CA2813557A1 (en) 2012-04-12
KR20140009168A (ko) 2014-01-22
SG10202108581TA (en) 2021-09-29
IL225536B (en) 2019-03-31
CN103298928A (zh) 2013-09-11
CN103298928B (zh) 2016-04-20
EA201390509A1 (ru) 2013-08-30
MX361299B (es) 2018-11-30
CO6710946A2 (es) 2013-07-15
SG10201508252PA (en) 2015-11-27
AR083295A1 (es) 2013-02-13
KR20190034359A (ko) 2019-04-01
CA2813557C (en) 2021-05-04
EP2626418A4 (en) 2014-02-19
JPWO2012046730A1 (ja) 2014-02-24
ZA201303056B (en) 2013-12-23
US20200354405A1 (en) 2020-11-12
CN105802910A (zh) 2016-07-27
JP6298101B2 (ja) 2018-03-20
TW201623616A (zh) 2016-07-01
US10654892B2 (en) 2020-05-19
PH12013500654A1 (en) 2013-05-06
TWI608099B (zh) 2017-12-11
US12415833B2 (en) 2025-09-16
AU2011313327B2 (en) 2015-10-22
EA037547B1 (ru) 2021-04-12
US20130266958A1 (en) 2013-10-10
TW201217525A (en) 2012-05-01
KR20200018738A (ko) 2020-02-19
JP2018093870A (ja) 2018-06-21
JP6134139B2 (ja) 2017-05-24
MX2018008436A (es) 2021-12-08
IL225536A0 (en) 2013-06-27
JP2017006120A (ja) 2017-01-12
AU2011313327A1 (en) 2013-05-02
SG189287A1 (en) 2013-05-31
WO2012046730A1 (ja) 2012-04-12
IL245440A0 (en) 2016-06-30
ES2849187T3 (es) 2021-08-16
KR102079480B1 (ko) 2020-02-19
EP2626418B8 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
NZ703560A (en) Method for activating helper t cell
NZ600732A (en) Oxyntomodulin peptide analogue
Tugyi et al. The effect of cyclization on the enzymatic degradation of herpes simplex virus glycoprotein D derived epitope peptide
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
NZ600731A (en) Oxyntomodulin peptide analogue
CY1118664T1 (el) Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου
NZ597692A (en) Anti-IGF antibodies
NZ708990A (en) Method for activating helper t cell
MX2014000210A (es) Peptidos procoagulantes y sus derivados, y usos para estos.
RU2011132212A (ru) Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция
NZ597923A (en) Protein glycosylation
RU2009128979A (ru) Hla*1101-ограниченный пептид wt1 и содержащая его фармацевтическая композиция
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
NZ601591A (en) Methods for treating pancreatic cancer
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
NZ599590A (en) Factor involved in latent infection with herpesvirus, and use thereof
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
WO2011135222A3 (fr) Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
NZ586074A (en) LCLRP peptides, constructs and uses thereof
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
MX339559B (es) Conjugados de igf-i poli(etilenglicol).
Lu et al. A new strategy for synthesis of branched cyclic peptide by Asn side-chain hydrazide ligation
JP2013522174A5 (https=)
CA2819463C (en) Tomm34 peptides and vaccines including the same

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 OCT 2018 BY HENRY HUGHES IP LIMITED

Effective date: 20170406

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2019 BY HENRY HUGHES IP LIMITED

Effective date: 20180911

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2020 BY HENRY HUGHES IP LIMITED

Effective date: 20190827

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2021 BY HENRY HUGHES IP LIMITED

Effective date: 20200915

ASS Change of ownership

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, , JP

Effective date: 20210317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2022 BY HENRY HUGHES IP LIMITED

Effective date: 20210927

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2023 BY HENRY HUGHES IP LIMITED

Effective date: 20220920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2024 BY HENRY HUGHES IP LIMITED

Effective date: 20230919

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2025 BY HENRY HUGHES IP LIMITED

Effective date: 20241002